Prescient onboards former Array Biopharma executive

By Trevor Hoey. Published at Oct 29, 2018, in ASX Biotechs

Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.

Winkler brings 40 years’ experience in the international biotechnology and pharmaceutical space, with a focus on oncology and inflammation. He has overseen the discovery and advancement of multiple new drugs into clinical development, with several demonstrating mid-to-late stage clinical success.

Especially noteworthy are the senior leadership positions Winkler previously held with pioneering targeted cancer drug developer, Array BioPharma (NASDAQ:ARRY), where he established and led the company’s licensing and collaboration efforts.

US$3.1 billion Array has engaged in cancer drug collaborations with Pfizer and Merck, and in 2013 entered a multi-year licensing and collaboration partnership with Loxo Oncology (NASDAQ:LOXO) to develop a number of promising new small molecule cancer drugs.

At Array, Winkler provided leadership for multiple teams working in drug discovery, translational research and clinical development, as well as managing several collaborations with multinational pharmaceutical firms.

He also helped build an impressive pipeline of development drugs, with over 12 advancing toward Phase II or III studies.

Most recently, Winkler served as Vice President Discovery and Translational Biology with drug discovery and development company, FORMA Therapeutics, and Chief Scientific Officer with Arvinas Inc (NASDAQ:ARVN). He also worked with GlaxoSmithKline as Associate Director, Department of Oncology Research.

Winkler’s experience should be invaluable for PTX as the company advances its PTX-200 drug candidate — a novel pH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia.

PTX-200 is at various trial stages across a range of cancers, and its phase II study examining the outcomes in breast cancer patients is keenly anticipated, particularly after receiving encouraging efficacy signals in the phase 1B study with twice the expected response rate.

Prescient surges 50% as global markets tumble

PTX Managing Director and Chief Executive, Steven Yatomi-Clarke, said: “We are honoured to have such an experienced and talented leader join our team.”

“His contribution and expertise across target validation, early drug discovery, translational medicine and clinical and platform development, as well as fostering multiple industry collaborations, will help make a significant and positive difference to the growth of our business and our promising cancer therapy portfolio.”

Dr Winkler said: “Even though it is currently a small company, Prescient has unique and exciting drugs in development.”

“I am excited to join a small and passionate team and contribute to the important work of developing new treatments for people with cancer.”

This news comes less than a fortnight after PTX announced it had kicked off a collaboration agreement with a leading private US-based drug development company to develop new formulations of pH domain and Akt inhibitors. This pipeline collaboration builds on PTX’s knowledge gained during the development of PTX-200.

This development resulted in PTX’s shares surging nearly 50% from 7.2 cents to a high of 10.5 cents last week — a strong performance, given the substantial downturn in equities markets that was occurring in the background.

Where to invest $1,000 right now

When the experts at Next Investors have a stock pick, it may pay to listen.

The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.

They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.

Click the link below to see what they are currently investing in.


S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why is Australia’s leading small cap publication

Founded seven years ago, is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise. provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more. is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!